Foundation
Medicine, Inc. (NASDAQ:FMI) and Sarah Cannon Research Institute
(Sarah Cannon) today announced a collaboration focused on advancing
personalized medicine utilizing molecular information for patients
across Sarah Cannon’s cancer programs in the United States. The
organizations will gather results from Foundation Medicine’s full suite
of comprehensive genomic profiling (CGP) assays to personalize treatment
options for patients and to ultimately support improved outcomes.

Sarah Cannon is one of the world’s leading clinical research
organizations conducting community-based clinical trials across a global
network. Researchers can use Foundation Medicine’s CGP assays,
FoundationOne® for use with solid tumors, FoundationOne®
Heme for use with hematologic malignancies and FoundationACT™ for use as
a liquid biopsy, to identify eligible patients for participation in
Sarah Cannon’s clinical studies. Foundation Medicine’s CGP assays aid
treating physicians and researchers to more effectively screen and match
patients to early and late-phase clinical trials based on their genomic
information. Sarah Cannon will also integrate Interactive Cancer
Explorer®, Foundation Medicine’s physician facing decision support
portal, across its network to facilitate clinico-genomic knowledge among
researchers and to enhance patient access to precision therapeutics.

Additionally, Sarah Cannon and Foundation Medicine have entered into a
master research program agreement to collaborate on the development of
research studies, as well as clinical programs designed to evaluate and
establish the most appropriate use of Foundation Medicine’s assays into
clinical care pathways.

“Our physicians are at the forefront of clinical research through our
work with novel investigative therapies,” said Howard A. “Skip” Burris,
M.D., president, clinical operations and chief medical officer, Sarah
Cannon. “Clinical trials, particularly those where patients can be
molecularly matched to a study, are an integral part of effectively
treating many types of cancers and accelerating patient access to novel
therapies. We’re excited to collaborate with Foundation Medicine as we
continue to enhance access to molecular information, which helps improve
clinical care and inform research across our network.”

Sarah Cannon and Foundation Medicine will also work together to develop
training and educational programs that support the advancement of
personalized medicine, including work with Sarah Cannon’s Nurse
Navigator Program, a high-touch, personalized support program that
enables nurses to comprehensively manage a patient’s experience with
cancer.

“Precision medicine in cancer can be achieved by innovating new ideas
that accelerate patient access to novel compounds in development,” said
Steven Kafka, president and chief operating officer for Foundation
Medicine. “Together with Sarah Cannon, we believe we are in a unique
position to eliminate roadblocks to patient access, to integrate
genomics knowledge into clinical pathways and to extend that knowledge
across the cancer care continuum to accelerate research and drive better
outcomes for all patients.”

About Sarah Cannon Research Institute

Sarah Cannon Research Institute is the research arm of HCA’s global
cancer institute, Sarah Cannon. Focused on advancing therapies for
patients, it is one of the world’s leading clinical research
organizations conducting community-based clinical trials throughout the
United States and United Kingdom. Sarah Cannon’s network of strategic
sites includes more than 275 physicians who engage in research. The
organization has led more than 250 first-in-man clinical trials since
its inception in 1993, and has been a clinical trial leader in more than
two-thirds of approved cancer therapies over the last 10 years.
Additionally, Sarah Cannon offers management, regulatory, and other
research support services for drug development and industry sponsors as
well as strategic investigator sites through its contract research
organization (CRO), Sarah Cannon Development Innovations (formerly known
as SCRI Development Innovations). For more information, visit sarahcannon.com.

About Foundation Medicine

Foundation Medicine (NASDAQ:FMI) is a molecular information company
dedicated to a transformation in cancer care in which treatment is
informed by a deep understanding of the genomic changes that contribute
to each patient's unique cancer. The company offers a full suite of
comprehensive genomic profiling assays to identify the molecular
alterations in a patient's cancer and match them with relevant targeted
therapies, immunotherapies and clinical trials. Foundation Medicine's
molecular information platform aims to improve day-to-day care for
patients by serving the needs of clinicians, academic researchers and
drug developers to help advance the science of molecular medicine in
cancer. For more information, please visit http://www.FoundationMedicine.com
or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine®, FoundationOne®
and FoundationOne® Heme are registered
trademarks and FoundationACT™ is a trademark of Foundation Medicine, Inc.

This press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements regarding the implementation
of the collaboration between Foundation Medicine and Sarah Cannon, the
ability of Foundation Medicine’s CGP assays to effectively screen and
match Sarah Cannon patients to early and late-phase clinical trials; the
ability of Foundation Medicine’s Interactive Cancer Explorer to
integrate into physician practice, to enhance the development of ability
of clinico-genomic information and to support access for patients to
precision medicine in the treatment of cancer; and the development and
enhancement of research studies conducted by Sarah Cannon as a result of
the collaboration. All such forward-looking statements are based on
management’s current expectations of future events and are subject to a
number of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied by
such forward-looking statements.These risks and uncertainties
include the risks that the collaboration is not implemented as quickly
or as broadly as anticipated; Foundation Medicine's CGP assays do not
perform as expected; the Interactive Cancer Explorer is not widely
adopted or used by physicians at Sarah Cannon; the genomic information
identified by Foundation Medicine’s CGP assays does not facilitate
access to relevant targeted therapies or clinical trials as readily as
expected; and the risks described under the caption “Risk Factors” in
Foundation Medicine’s Quarterly Report on Form 10-K for the year ended
December 31, 2015, which is on file with the Securities and Exchange
Commission, as well as other risks detailed in Foundation Medicine’s
subsequent filings with the Securities and Exchange Commission.All
information in this press release is as of the date of the release, and
Foundation Medicine and Sarah Cannon undertake no duty to update this
information unless required by law.

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her
physician.